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Summary
Lithium inhibits inositol monophosphatase at thera-
peutically effective concentrations, and it has been
hypothesized that depletion of brain inositol levels is
an important chemical alteration for lithium’s thera-
peutic efficacy in bipolar disorder. We have employed
adult rat cortical slices as a model to investigate the
gene regulatory consequences of inositol depletion
effected by lithium using cytidine diphosphoryl-diacyl-
glycerol as a functionally relevant biochemical marker
to define treatment conditions. Genes coding for the
neuropeptide hormone pituitary adenylate cyclase ac-
tivating polypeptide (PACAP) and the enzyme that
processes PACAP’s precursor to the mature form,
peptidylglycine -amidating monooxygenase, were
upregulated by inositol depletion. Previous work has
shown that PACAP can increase tyrosine hydroxylase
(TH) activity and dopamine release, and we found that
the gene for GTP cyclohydrolase, which effectively
regulates TH through synthesis of tetrahydrobiop-
terin, was also upregulated by inositol depletion. We
propose that modulation of brain PACAP signaling
might represent a new opportunity in the treatment of
bipolar disorder.
Introduction
Bipolar disorder (BD) is a chronic psychiatric illness
characterized by recurrent episodes of depression and
mania with prevalence estimated at 1%–2% lifetime
risk in the United States (DSM-IV, 1994; Weissman et
al., 1988). Lithium is effective at stabilizing mood, re-
ducing the rate of relapse, and reducing suicide in BD
(Burgess et al., 2003; Dinan, 2002; Goodwin et al.,
2003). Although valproate and lamotrigine have been
introduced as maintenance therapies with efficacy
demonstrated in clinical trials, lithium is still a front-line
treatment for BD, despite significant side effects (Bow-*Correspondence: philip_brandish@merck.com
3Present address: The Broad Institute, One Kendall Square, Cam-
bridge, Massachusetts 02139.den et al., 2000; Bowden et al., 2003; Dinan, 2002). The
etiology of the disease and the mechanism of action of
lithium remain to be determined, and this has under-
standably stifled development of safer, more effective
medicines.
There are numerous hypotheses for the mechanism
of action of lithium in BD, and these have been re-
viewed (Gould et al., 2004; Gurvich and Klein, 2002).
Glycogen synthase kinase 3 (GSK3) and inositol mono-
phosphatase (IMPase) are both inhibited by lithium and
have been topics of considerable study as potential
therapeutic targets in BD.
An effect of lithium on brain inositol levels was dem-
onstrated more then 30 years ago (Allison and Stewart,
1971). Inositol phosphates and inositol-containing phos-
pholipids (phosphoinositides) constitute an array of cell
signaling molecules with diverse functions (Irvine and
Schell, 2001; Majerus, 1992). Most notably, activation
of cell surface receptors can activate hydrolysis of
phosphatidylinositol-4,5-bisphosphate (PIP2) by phos-
pholipase C (PLC) to produce inositol-1,4,5-trisphos-
phate (IP3), which is a second-messenger molecule. IP3
binds to its cognate receptor to trigger release of Ca2+
from the endoplasmic reticulum (ER) and a host of
downstream signaling events. Lithium inhibits two en-
zymes in the inositol pathway, namely inositol poly-
phosphate 1-phosphatase and IMPase, both uncom-
petitively with respect to substrate (Majerus, 1992).
Indeed, therapeutically relevant doses of lithium cause
accumulation of inositol phosphates in the brains of
rats and mice (Atack et al., 1992; Sherman et al., 1986).
The “inositol depletion” hypothesis of lithium’s action in
BD was formulated by Berridge (Berridge et al., 1989).
Simply put, lithium blocks IMPase and the recycling of
inositol into inositol lipids. This leads to a reduction in
PIP2 and a reduction in the ability of the cell (neuron) to
respond to a stimulus by making IP3 to stimulate an
increase in intracellular Ca2+ concentration. Thus, neu-
ronal excitability is reduced, and this somehow leads
to normalization of mood. Further, the hypothesis says
that because brain cells have limited access to dietary
inositol they are more dependent on recycled inositol
than cells in the periphery, giving rise to a therapeutic
window (Berridge et al., 1989, and references therein).
There is a delay of 5–10 days between commence-
ment of lithium therapy and therapeutic benefit (Lenox
and Manji, 1998). The basis for this is unknown, but it
is credible that gene regulatory events and subsequent
changes in protein expression are required. The benefi-
cial effect of lithium in BD may be derived from a com-
bination of GSK3- and inositol-mediated events, mean-
ing that both pathways need to be studied and their
contributions dissected by performing experiments
with lithium under inositol-depleted and inositol-replete
conditions. In yeast cells, a pathway regulated by inosi-
tol levels is emerging. However, in mammalian cells
much less is known (Loewen et al., 2004; Schuller et
al., 1995). In the present work, we have focused our
effort on identifying genes whose expression levels are
changed by lithium’s action on the inositol pathway.
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Figure 1. Accumulation of CDP-DAG in Adult Rat Brain Cortical i
Slices s
Slices were prepared and dispensed two per well into culture me-
dium containing 2 mM LiCl as described in the Experimental Pro- a
cedures section. Tritiated cytidine, carbachol, and inositol were d
added as described for each panel, t = 0 being the time at which
the slices were dispensed to the medium. At the indicated time,
the tissue was removed and CDP-DAG estimated as the amount
of organic solvent-extractable radioactivity. Statistical analysis was
Dperformed using ANOVA followed by Tukey’s post test: *p < 0.01
fversus LiCl + carbachol treatment. (A) Where indicated in the figure,
t10 mM inositol was added at t = 0, 10 Ci of 3H-cytidine at t = 1
phr, carbachol to 50 M at t = 2 hr. At t = 3 hr, tissue was processed
ffor analysis of CDP-DAG. Data shown are means (n = 4) ± SD. (B)
tWhere indicated in the figure, 10 mM inositol was added at t = 0,
u10 Ci of 3H-cytidine at t = 22 hr, carbachol to 50 M at t = 23 hr. At
4t = 24 hr, tissue was processed for analysis of CDP-DAG.Inositol is present at high (millimolar) concentrations
n the brain (Lubrich et al., 1997), such that a modest
eduction in its concentration does not necessarily
ean it has become a limiting metabolite. When inosi-
ol becomes limiting in the synthesis of phosphatidyl-
nositol (PI) by PI synthase, cytidine diphosphoryl-diac-
lglycerol (CDP-DAG) accumulates, and particularly so
hen a cell (or brain slice) has been activated to pro-
uce IP3 and DAG from PIP2 (PI turnover) in the pres-
nce of lithium (Godfrey, 1989; Stubbs and Agranoff,
993). CDP-DAG accumulation is therefore a surrogate
arker for functional inositol depletion, and it is readily
easurable by radiolabeling with 3H-cytidine. Stimula-
ion of PI turnover via agonism of muscarinic receptors
ith carbachol is one approach that has been used
idely to study the PI pathway and can similarly be
sed to study modulation of neuronal (and brain) sig-
aling caused by inhibition of IMPase, in this case by
ithium. Stubbs and Agranoff have demonstrated accu-
ulation of CDP-DAG in acute (1–2 hr) studies using
ross-chopped slices of adult rat cortex treated with
arbachol and LiCl (Stubbs and Agranoff, 1993). Adult
at cortical slices thus constitute a potential model for
rofiling the gene regulatory consequences of inositol
epletion where the treatments used can be directed
y a relevant biochemical marker, i.e., CDP-DAG.
esults
cute Rat Brain Cortical Slices as an Ex Vivo
odel of Brain Inositol Depletion
here is little precedent for extended, multiday culture
f adult rat cortical slices. Therefore, we selected 24 hr
s a time frame which would be long enough for gene
xpression changes to occur, but short enough that the
lices could survive while still being relevant to the clin-
cal disorder. This time frame is relevant because al-
hough symptomatic relief takes 5–10 days to occur, we
xpected, based on literature precedent, that inositol
epletion would occur rapidly in the presence of car-
achol and LiCl (e.g., <1 hr), leaving almost the entire
ime course for gene expression change. In contrast,
ymptomatic relief requires several events, including
rug accumulation, biochemical change, gene regula-
ory change, and manifestation of benefit, each of
hich may take 1–2 days or more. To characterize the
xperimental system, we measured CDP-DAG accumu-
ation with different treatments and at different times,
solated and quality tested total RNA, and imaged
lices stained with propidium iodide or Hoechst 33342.
The goal of the experiment was to identify genes that
re regulated as a consequence of inositol depletion
ue to blockade of inositol phosphatases by lithium inata shown are means (n = 3) ± SD. (C) Where indicated in the
igure, 10 mM inositol was added at t = 0, 10 Ci of 3H-cytidine at
= 1 hr, carbachol to 50 M at t = 2 hr. At t = 3 or 24 hr, tissue was
rocessed for analysis of CDP-DAG. Data shown are means (n = 2
or 3 hr, n = 3 for 24 hr) ± SD. For the 24 hr data, the effect of
reatment was not significant: ANOVA p = 0.064. The individual val-
es for the LiCl + carbachol group at 24 hr were 153, 556, and
54 cpm.
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863the presence of an agonist that activates the PI path-
way. Such genes would be up- or downregulated by
treatment with LiCl and carbachol versus LiCl alone,
and that regulation would be wholly or partially pre-
vented by addition of excess inositol. Therefore, we
measured accumulation of CDP-DAG in fresh and DIV1
slices treated with such combinations of LiCl, car-
bachol, and inositol (Figure 1). Concentrations of lith-
ium associated with efficacy in bipolar disorder are in
the 0.5–1.5 mM range (Lenox and Manji, 1998). In the
presence of 2 mM LiCl, treatment of fresh slices with
50 M carbachol caused a robust accumulation of
CDP-DAG, which was completely prevented by inclu-
sion of 10 mM inositol in the culture medium (Figure
1A). The same pattern of CDP-DAG accumulation was
observed when the same treatments were applied at
DIV1, although the amount of radioactivity measured in
the slices treated with LiCl and carbachol was less than
in fresh slices (Figure 1B). These data indicate that the
biochemical function of the slices is preserved at DIV1.
We also investigated the time course of CDP-DAG ac-
cumulation (Figure 1C). Fresh slices were labeled with
3H-cytidine and treated with combinations of LiCl, car-
bachol, and inositol, and the amount of CDP-DAG was
measured (as radioactivity) at 1 or 22 hr after addition
of carbachol. The amount of CDP-DAG in slices treated
with LiCl + carbachol appeared to be elevated after 22
hr compared to LiCl alone, or LiCl + carbachol + inosi-
tol, although a treatment effect did not reach statistical
significance. A reduced amount of radiolabeled CDP-
DAG could result from increased de novo inositol syn-
thesis, but alternatively could be due to metabolism or
other degradation of the radiolabeled species to effec-
tively wash out the radiolabel.
Preliminary studies found that total RNA isolated
from slices maintained in the presence of 1 mM LiCl
was of consistent and acceptable quality (28S/18S
ratio > 0.8, Rosetta Bioinformatics standard quality
control metric), whereas total RNA isolated from slices
maintained in the absence of LiCl was always severely
degraded and low in yield (data not shown). We took
this to be a manifestation of the well-documented pro-
tective properties of LiCl against neurotoxic insults
such as those that occur during slice preparation, e.g.,
hypoxia and glutamate release (Jope and Bijur, 2002;
Nonaka et al., 1998; Ren et al., 2003), and as a positive
indication of slice viability. This led us to the treatment
set design used in the experiments noted so far (LiCl,
LiCl + carbachol, LiCl + carbachol + inositol) instead of
the intuitive configuration (carbachol, carbachol + LiCl,
carbachol + LiCl + inositol). Analysis of RNA samples
from slices from one of the two animals that were used
in the microarray study described below are shown in
Figure 2. ANOVA found no significant effect (p > 0.05)
of treatments on yield or 28S/18S ratio for this sample
set. The same was true for a combined analysis of all
six RNA sample sets used in this work.
We attempted to assess the viability of freshly pre-
pared and 1-day-old drug-treated brain slices by stain-
ing them with propidium iodide, a membrane-imperme-
able dye that only stains nonviable cells, or with
Hoechst 33342, which stained DNA from all cells
(Bonde et al., 2002; Kristensen et al., 2003). Z series of
images were acquired using confocal microscopy fromFigure 2. Adult Rat Brain Cortical Slice RNA Quality Control Data
(A) Pseudo-gel image of RNA samples extracted from slices treated
for 24 hr with 2 mM LiCl (lanes 1 through 4), 2 mM LiCl + 50 M
carbachol (lanes 5 - 8), or 2 mM LiCl + 50 M carbachol + 10 mM
inositol (lanes 9 through 12). Purified total RNA was electropho-
resed on an Agilent BioAnalyzer using a Nano RNA chip.
(B) Electropherogram of a single RNA sample from a pair of slices
treated with 2 mM LiCl + 50 M carbachol.outer cortical regions under all conditions (due to ease
of identification of this region) to compare the number
of nuclei labeled for each treatment. Representative
maximum projection images illustrate nuclear staining
of freshly isolated brain slices stained with Hoechst or
propidium iodide (Figure 3A). We observed Hoechst
staining up to 60–80 m within slices, while propidium
iodide penetrated slices only to a depth of 30–40 m,
and so z series of images were obtained only to a depth
of 40 m for both staining conditions (Figure 3B). It
should be noted that the surface of the slice was ex-
pected to contain a substantial proportion of nonviable
cells due to the mechanical trauma of slice preparation
and that this method is limited in that it does not give
information about the viability of cells deeper within the
slice (total 350 m). The considerable variability in the
number of Hoechst-labeled cells (i.e., total cell number)
per image area from slice to slice precluded reliable
estimation of the viable to nonviable ratio (Figure 3C).
Although ANOVA detected a significant difference in
the number of propidium iodide-stained cells between
day 1 LiCl + carbachol + inositol and fresh or day 1 LiCl
slices, the data do not point to a progressive deteriora-
tion during the 24 hr incubation or deterioration specifi-
cally associated with prolonged treatment with car-
bachol.
These three avenues of data led us to conclude that
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a(A) Maximum-intensity projection from a representative slice
tstained immediately following sectioning at day 0. The nuclei in the
tHoechst-stained section is pseudocolored green, while the propid-
aium iodide-stained section is pseudocolored red. Scale bar, 155 m.
(B) A maximum projection tilt series was created from the same e
slice as in (A) to visualize slice thickness from a side-on view per- a
pendicular to the plane of the slice. Scale bar, 30 m. t
(C) The number of labeled nuclei measured in Hoechst- (dark bar) T
and PI-stained (clear bar) sections from day 0 and day 1 slices
ufollowing different treatments. No Tx., no treatment; L, 2 mM LiCl;
gLC, 2 mM LiCl + 50 M carbachol; LCI, 2 mM LiCl + 50 M car-
bachol + 10 mM inositol. The data are means ± SD from four to six
regions from n = 3 slices for each condition. The number of nuclei s
labeled with Hoechst was not statistically different among the dif- E
ferent treatment groups (p > 0.05 ANOVA and Student’s t test). The t
LiCl only and the day 0 cultures showed significantly less labeling m
compared to the LCI condition (p < 0.05 by ANOVA followed by
5Tukey’s post test).
e
v
ain rat brain cortical slices maintained in the manner de-
sscribed, and perturbed with the treatments described,
i
integrity and function at DIV1 was sufficient to warrant
o
proceeding with the microarray analysis of the RNA s
samples collected. p
t
Microarray Identification of Candidate r
Inositol-Regulated Genes f
The three different treatments, 2 mM LiCl (L), 2 mM LiCl + e
50 M carbachol (LC), and 2 mM LiCl + 50 M car- s
ubachol + 10 mM inositol (LCI), were carried out withour replicates each. The experiment was performed
ith two animals, on separate days, ultimately yielding
total of 24 RNA samples (two animals × three treat-
ents × four biological replicates). We used a two fluor,
wo color, cohybridization microarray technology, where
he output is the log of the ratio of the expression level
f a given gene in one sample relative to the same gene
n a second sample. Since the LC treatment condition
s different from the other two by one variable, we des-
gnated that as the control treatment for the purpose of
he microarray experiment even though conceptually L
nd LCI are control (inositol replete) states and LC is
he perturbed state (inositol depleted). This experimen-
al design then makes two comparisons: L versus LC,
nd LCI versus LC. In fact, we took a small portion of
ach of the eight LC samples and pooled them to make
reference sample. Each individual RNA sample would
hen be compared to the pool-of-LC reference sample.
his includes the individual LC samples, which allowed
s to include the sample-to-sample variability of the LC
roup in our statistical testing.
RNA was amplified using a two-round reverse tran-
cription/in vitro transcription protocol and dye labeled.
ach amplified, labeled RNA sample was compared to
he LC reference sample by cohybridization to custom-
ade Agilent oligonucleotide arrays (designated Rat
0k v2.1 Array 1) with one fluor-reversed pair (FRP) for
ach sample. Differential expression in the test sample
ersus LC reference sample was expressed as the log-
rithm of the ratio of signal in the sample channel to
ignal in the control pool channel (log ratio). A reporter
s defined as the 60-mer oligonucleotide that is present
n the microarray chip. A single gene may be repre-
ented in the array by more than one reporter. As a
reliminary assessment of the microarray data we plot-
ed the number of reporters for which the mean log
atio value was significantly different than zero (i.e., dif-
erentially regulated compared to the pool-of-LC refer-
nce sample) with an associated p value less than a
et number over a range of arbitrarily set p values (Fig-
re 4). This analysis immediately told us that the num-igure 4. Global Preliminary Assessment of the Microarray Data Set
he number of statistically significantly regulated genes in each
reatment group versus the LiCl + carbachol pool sample at varying
ut off levels for significance. For any given cut off p value, the
umber of genes significantly regulated in the LiCl + carbachol
reatment group represents the false-positive rate. The numbers of
ignificantly regulated genes in the LiCl and LiCl + carbachol +
nositol groups are several-fold larger than the false-positive rate,
rrespective of the p value used to determine significance.
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865bers of statistically significant differences between L
and the pool-of-LC reference sample, and between LCI
and the pool-of-LC reference sample were many fold
greater than the differences between LC and the pool-
of-LC reference sample (false positives) irrespective of
the stringency of analysis. We also performed cluster-
ing analysis of the individual samples by log ratio value
across reporters (Figure S1 in the Supplemental Data
available with this article online). This analysis told us
that the variability between animals/day-of-experiment
was greater than the variability between treatment rep-
licates from a single animal.
Given the properties of the microarray data, we
elected to analyze the data segregated by animal as
well as analyzing the combined data set. Note that the
above analyses consider comparisons of treatment
replicates versus LC reference pool and therefore do
not take into account the variability in the LC treatment
group. To identify regulated genes for further analysis,
we must take the variability in the LC treatment group
into account by comparing the log ratio values from the
L group versus the log ratio values from the LC group,
and similarly for the LCI group versus the LC group. A
purely biological feature of this experiment is that inosi-
tol-responsive genes will only be regulated in those
cells in the slice preparation where inositol is depleted,
although secondary effects reaching other cells are
possible. We therefore expect that any regulation will
be diluted against the total compliment of mRNA for
that gene present in the slice. Based on these consider-
ations and on the preliminary characterization of the
data, we set the following criteria for a reporter/gene to
be considered “of interest”:
1. p < 0.05 for both L versus LC and LCI versus LC
in the data from the two animals combined.
2. p < 0.224 (square root of 0.05) for both L versus LC
and LCI versus LC in the data from each animal.
3. Fold change R 1.3 up or down (but in the same
direction) for L versus LC and LCI versus LC in the
data from the two animals combined.
We set rather low stringencies for individual compari-
sons and did not correct for multiple testing expecting
that the false-positive rate would instead be minimized
to a degree by the requirement for coincident regulation
above the threshold magnitude (fold change R 1.3) in
both the L versus LC and LCI versus LC comparisons.
Also, because we intended to do a confirmation study
using real-time quantitative PCR, we were less con-
cerned about minimizing false positives, but we were
keen to minimize false negatives. The second criterion
was included to avoid reporters/genes being indicated
as significant in the aggregate solely on the basis of
data from a single animal.
The criteria were satisfied for 173 reporters (171
genes). Probe sequences, gene symbols, and microar-
ray results for all these genes are listed in Table S1, and
a heatmap showing clustering by sample and by gene
illustrates those data (Figure S2). These were consid-
ered candidate inositol-regulated genes. Among the 171
genes, 60 are known or could be annotated with confi-
dence using public database information. The myristo-ylated alanine-rich C-kinase substrate (MARCKS) protein
has been reported to be regulated by lithium in an inosi-
tol-dependent manner in immortalized hippocampal
(HN33) cells (Wang et al., 2001). The MARCKS gene,
the rat homolog being MARCKS-like protein (Mlp), was
not found to be regulated by inositol depletion in this
study. The microarray used included two separate re-
porters for Mlp.
Validation of Candidate Inositol-Regulated Genes
Using Real-Time Quantitative PCR
The functionally annotated genes were selected for
confirmation using real-time quantitative PCR (RT-QPCR),
as well as two of the nonannotated sequences where
the microarray data was highly statistically significant
(LOC286960 and LOC140610). For RT-QPCR analysis,
we prepared new, independent RNA samples: four ani-
mals × three treatments × three biological replicates per
animal. The yield of RNA from individual samples
(average 2.1 g total RNA) was insufficient for RT-
QPCR analysis of 64 genes (60 test genes and 4 in-
ternal reference genes), so we amplified messenger
RNAs using the aRNA method originally devised by Eb-
erwine (Phillips and Eberwine, 1996). Three samples
were not carried forward to RT-QPCR analysis because
of no product or very low yield from the aRNA amplifi-
cation procedure. Two of the annotated genes (Cxadr
and Sat) were not included in the study because the
RT-QPCR assay did not work in a pilot trial.
The RT-QPCR results are given in Table S3. Correla-
tion between the RT-QPCR results and the microarray
results was rather modest (Figure S3), but we attribute
this to a high false-positive rate anticipated from our
statistical cut-off values used in analysis of the microar-
ray data and to the small fold changes measured
(average of 1.6-fold in either direction for candidate ino-
sitol-regulated genes) rather than poor data quality. At
this stage of the study, we were concerned to minimize
the false-positive rate, that is, to be highly confident
that the genes identified are specifically regulated by
inositol depletion caused by LiCl and carbachol treat-
ment. To this end, we set the following two criteria:
1. p < 0.025 for both LC versus L (inositol depletion)
and LCI versus LC (inositol repletion).
2. Fold changeR 1.3 up or down (but in the opposite
direction) for both LC versus L and LCI versus LC.
Twenty genes out of the 60 tested satisfied these cri-
teria and are shown above the line in Table 1. Genes
below the line do not meet the criteria set out above,
but still had p values < 0.05 for both comparisons and
so were not dismissed. As noted above in consider-
ation of the correlation between the RT-QPCR data and
the microarray data, this confirmation rate reflects the
low stringency deliberately set for identification of can-
didate inositol-regulated genes in the microarray por-
tion of the study. All of the confirmed genes were
upregulated by inositol depletion and downregulated
by inositol repletion, but not down- and upregulated,
respectively. We are not aware of any bias or system-
atic error in the experiment, the technology, or the data
analysis that would favor detection of genes upregu-
Neuron
866Table 1. RT-QPCR Results for Confirmed and “Near-Miss” Inositol-Regulated Genes
Change in Inositol Status
Depletion (LCa versus L) Repletion (LCI versus LC)
Geneb Fold Change p Value Fold Change p Value
C4bpa [ 7.10 <0.0001 Y 4.42 <0.0001
Sarcosin [ 7.71 <0.0001 Y 2.77 <0.0001
Mustang [ 3.00 <0.0001 Y 1.71 0.0009
Adcyap1 [ 3.11 <0.0001 Y 2.01 0.0010
Mmp12 [ 5.53 <0.0001 Y 2.33 0.0010
Nox1 [ 2.98 <0.0001 Y 2.14 0.0012
Edn2 [ 6.81 <0.0001 Y 3.53 0.0013
Mmp10 [ 2.40 <0.0001 Y 1.62 0.0015
Slc26a3 [ 2.50 <0.0001 Y 1.94 0.0016
Atf3 [ 1.57 0.0004 Y 1.47 0.0019
Gch [ 1.42 0.0038 Y 1.52 0.0008
LOC286960 [ 2.99 0.0038 Y 3.80 0.0005
Gpr88 [ 2.18 0.0060 Y 2.30 0.0037
Cbr1 [ 1.81 0.0067 Y 1.78 0.0085
Crem-1 [ 1.47 0.0006 Y 1.31 0.0115
Cited2 [ 1.67 0.0013 Y 1.47 0.0120
MS1 [ 4.24 <0.0001 Y 1.98 0.0147
Filip [ 1.52 0.0172 Y 1.50 0.0208
Kras2 [ 1.49 0.0225 Y 1.62 0.0064
Slc2a2 [ 1.82 0.0245 Y 1.86 0.0200
Pam [ 2.38 0.0005 Y 1.66 0.0268
Tnfip6 [ 2.21 <0.0001 Y 1.36 0.0283
Kcna4 [ 1.73 0.0175 Y 1.65 0.0290
Hcn1 [ 1.92 0.0308 Y 2.08 0.0163
Arpp19 [ 1.24 0.0309 Y 1.26 0.0221
Rptpk [ 1.53 0.0046 Y 1.35 0.0369
Rgs4 [ 1.66 0.0390 Y 1.69 0.0349
Stxbp5 [ 1.29 0.0437 Y 1.37 0.0139
Syt12 [ 1.27 0.0490 Y 1.29 0.0357
Genes names and data are italicized if the fold change for either comparison is <1.3.
aL, LiCl; LC, LiCl + carbachol; LCI, LiCl + carbachol + inositol.
bThe data are ranked in ascending order by the numerically higher of the two p values associated with each gene.lated by inositol depletion over downregulated genes. A
lIt is quite possible that this is a real biological phenom-
enon, and presently we have no reason not to believe c
mthis interpretation.
Table 2 lists the confirmed inositol-regulated genes, c
othe human homologs, and the full name of the human
homolog derived from the NIH/NCBI Entrez Gene web a
facility (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?
db=gene) as well as synonyms. In addition to literature t
ssearch evaluation of these newly identified inositol-reg-
ulated genes, we compared the cytogenetic location of g
athe human homologs of the 20 confirmed inositol-regu-
lated genes (as well as the “near-miss” genes) to a cat- g
ialog of BD risk loci prepared from the literature. For
inositol-regulated genes at or close to BD risk loci, we v
tcalculated the distance of the gene from the nearest
risk locus, typically a sequence tagged site (STS) f
kmarker, based on chromosomal locations retrieved
through the UC Santa Cruz Human Genome Browser l
iGateway (July 2003 assembly) at http://genome.ucsc.
edu/. Two genes that had p values < 0.05 for both com-
parisons in the RT-QPCR study were located within 1 D
million base pairs (MB) of a bipolar disorder risk locus.
ADCYAP1 is one of six genes identified as possible L
brisk genes in a recent study of bipolar I disorder in a
Costa Rican population (McInnes et al., 2001). The t
iADCYAP1 gene is 0.26 MB from D18S59 (STS markerFM178XC3) at chromosome 18p11.3, which was in
inkage disequilibrium. Human SLC26A3 is located at
hromosome 7q31, and is 0.97 MB from D7S501 (STS
arker AFM199VB2), which was identified as a risk lo-
us marker by Detera-Wadleigh et al. in a genome scan
f 22 bipolar disorder pedigrees (Detera-Wadleigh et
l., 1999).
Specific transcription factors and a consensus inosi-
ol-choline promoter response element have been de-
cribed in yeast that allow the organism to regulate
enes according to cellular inositol levels (Schuller et
l., 1995). Both lithium and valproate can regulate
enes such as INO1 and INO2 in yeast via depletion of
nositol (Vaden et al., 2001), and phosphatidic acid has
ery recently been identified as the effector molecule
hat couples inositol levels to regulation of transcription
actor activity (Loewen et al., 2004). To the best of our
nowledge, none of the yeast homologs of the genes
isted in Table 1 have been shown to be regulated by
nositol.
iscussion
ithium acts on many molecular pathways in the brain,
ut in this gene expression profiling study we were able
o specifically associate the regulation of genes with
nositol depletion arising from blockade by LiCl of
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867Table 2. Annotation and Functional Summary of Confirmed Inositol-Regulated Genes
Rat Gene Symbol Human Homolog Full Name Synonyms
C4bpa C4BPA complement component 4 binding protein, alpha
Sarcosin KBTBD10 kelch repeat and BTB (POZ) domain containing 10 Sarcosin
Mustang MUSTN1 musculoskeletal, embryonic nuclear protein 1 mustang
Adcyap1 ADCYAP1 adenylate cyclase activating polypeptide 1 (pituitary) PACAP
Mmp12 MMP12 matrix metalloproteinase 12 (macrophage elastase) HME, MME
Nox1 NOX1 NADPH oxidase 1 GP91-2, MOX1, NOH-1, NOH1
Edn2 EDN2 endothelin 2 ET2
Mmp10 MMP10 Matrix metalloproteinase 10 Stromelysin 2, transin
Slc26a3 SLC26A3 solute carrier family 26, member 3 (sulfate) CLD, DRA
Atf3 ATF3 activating transcription factor 3
Gch GCH1 GTP cyclohydrolase 1 (dopa-responsive dystonia) DYT5, GCH, GTPCH1
LOC286960 not known Preprotrypsinogen IV (rat only)
Gpr88 GPR88 G-protein coupled receptor 88 STRG
Cbr1 CBR1 carbonyl reductase 1
Crem (1) CREM cAMP responsive element modulator ICER
Cited2 CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich MRG1, P35SRJ
carboxy-terminal domain, 2
MS1 STARS striated muscle activator of Rho-dependent signaling
Filip FILIP1 filamin A interacting protein 1
Kras2 KRAS2 v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog C-K-RAS, K-RAS2A, K-RAS2B,
K-RAS4A, K-RAS4B, KI-RAS,
KRAS, RASK2
Slc2a2 SLC2A2 solute carrier family 2 (facilitated glucose transporter), member 2 GLUT2
Pam PAM peptidylglycine alpha-amidating monooxygenase PAL, PHM
Tnfip6 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 TSG6
Kcna4 KCNA4 potassium voltage-gated channel, shaker-related subfamily, HBK4, HK1, HPCN2, HUKII,
member 4 KCNA4L, KCNA8, KV1.4, PCN2
Hcn1 HCN1 hyperpolarization activated cyclic nucleotide-gated potassium BCNG-1, BCNG1, HAC-2
channel 1
Arpp-19 ARPP-19 cyclic AMP phosphoprotein, 19 kD ARPP-16, ARPP16, ARPP19
Rptpk PTPRK protein tyrosine phosphatase, receptor type, K R-PTP-kappa
Rgs4 RGS4 regulator of G-protein signalling 4 RGP4
Stxbp5 STXBP5 syntaxin binding protein 5 (tomosyn) LGL3, LLGL3
Syt12 SYT12 synaptotagmin XII SRG1, SYT11IMPase. Moreover, we can correlate the gene expres-
sion data with biochemical data that clearly demon-
strate that the treatment conditions manipulate the
slice preparation in the intended fashion. In this way,
we know the proximal targeted biochemical pathway
that leads to regulation of the genes, even though we
do not yet know what signaling events lie in between.
Compared to many microarray studies, the number
of genes confidently identified as regulated in this
study may be deemed small. Several factors may con-
tribute to this, including the high stringency that we set
for confirmation and heterogeneity of the slice prepara-
tion leading to dilution of signal from cell type-specific
events. Perhaps more significant though, the condi-
tions of the study are rather specific in that to be called
“regulated,” a gene must be regulated by the action of
carbachol in the presence of LiCl, and that regulation
must be wholly or partially prevented by the addition
of inositol. Because of these stringent conditions, and
because the RT-QPCR study was performed using in-
dependent samples prepared several months after
those used for microarray profiling, we have a very high
degree of confidence in the results of this study. In the
interest of brevity, we have focused discussion on ino-
sitol-regulated genes that by virtue of their function,
and of independent findings, suggest new directions
toward treatment of bipolar disorder. For example,
GPR88 is an orphan GPCR that is expressed predomi-nantly in the striatum and that bears highest homology
to the serotonin 1D receptor among other GPCRs (Mi-
zushima et al., 2000). A recent study showed expres-
sion of GPR88 to be regulated in rat prefrontal cortex
in an animal model of mania and by valproate treat-
ment, thus prioritizing this receptor for future study
(Ogden et al., 2004).
Among the genes identified, we considered AD-
CYAP1 especially interesting because it is a brain neu-
ropeptide signaling molecule and because it is located
close to a bipolar disorder risk locus on chromosome
18 (McInnes et al., 2001). ADCYAP1 is the gene for pitu-
itary adenylate cyclase activating polypeptide (PACAP),
which is a brain neuropeptide that shares homology
with vasoactive intestinal polypeptide (VIP) and acts
through three different GPCRs (Vaudry et al., 2000). Al-
though originally associated with the hypothalamus,
subsequent studies showed widely distributed CNS ex-
pression, including the cerebral cortex, indicating a
broader role than its name suggests (Mikkelsen et al.,
1994; Skoglosa et al., 1999). PACAP knockout mice
have a high neonatal mortality rate, but the surviving
adult mice have a profound psychomotor phenotype,
including general hyperactivity and explosive jumping
behavior in a novel environment, and increased explor-
atory behavior associated with reduced anxiety (Hashi-
moto et al., 2001). These mice also exhibit circadian
defects characterized by an attenuated phase advance
Neuron
868response to late subjective night light stimulation (Ka- b
waguchi et al., 2003). Aberrant circadian behavior has d
been discussed as a pathological defect in bipolar dis- b
order, and chronic lithium has been shown to regulate e
circadian behavior in animals (Lenox et al., 2002; Welsh c
and Moore-Ede, 1990). An independent knockout line a
was found to be cold sensitive, and results suggested u
that this was due to defects in catecholamine synthesis p
and thermoregulation (Gray et al., 2002). The Drosoph- f
ila homolog of PACAP is amnesiac, for which loss-of- d
function mutation impairs learning and memory and (
causes increased ethanol sensitivity (Hashimoto et al.,
2002). PACAP-specific receptor (Adcyap1r1, also called C
PAC1) knockout mice show defects in associative fear T
learning, and PACAP has concentration-dependent ef- d
fects on hippocampal synaptic plasticity (Hashimoto et c
al., 2002), but it remains to be seen if the PACAP knock- l
out mice have learning and memory deficits also. Inter- G
estingly, peptidylglycine α-amidating monooxygenase o
(Pam) only very narrowly failed to meet our criteria to w
be confirmed as an inositol-regulated gene in the RT- b
QPCR study (Table 1). PAM processes the PACAP pre- m
cursor to the mature PACAP-38 and PACAP-27 C-ter- c
minally α-amidated forms (Vaudry et al., 2000). Thus we a
have found coordinate upregulation of a neuropeptide I
hormone and the enzyme required to convert it to its w
active form. f
PACAP is expressed in many nuclei in the limbic sys- m
tem and the cortex, but its roles outside the hypothala- l
mus have only recently begun to be studied: PACAP s
has been shown to increase tyrosine hydroxylase (TH) n
protein activity and mRNA levels in vivo, in primary cell a
cultures, and in a dissociated rat nucleus accumbens
preparation (Moser et al., 1999; Vaudry et al., 2000, and E
references therein). Intracerebroventricular injection of
CPACAP increased dopamine release in the hypothala-
Amus in sheep (Anderson and Curlewis, 1998), but it has
Cnot been tested whether PACAP can also potentiate
Sdopamine signaling in nigral and ventral tegmental neu-
b
rons in vivo. The present study found that the gene for r
GTP cyclohydrolase (GCH) is upregulated by inositol (
depletion. GCH is the rate-limiting enzyme in the syn- 2
tthesis of tetrahydrobiopterin (BH4), which is the cofac-
btor for TH (Hyland et al., 2003). Synthesis of BH4 is a
slimiting factor for TH activity, and mutations in GCH
ecause dopa-responsive dystonia (Hyland et al., 2003).
c
Indeed, chronic treatment with lithium was found to t
increase TH protein levels in rat brain hippocampus and p
striatum, and to a minor extent in cortex (Chen et al., m
f1998).
(Two recent small-scale placebo controlled studies
sdemonstrated antidepressant efficacy for pramipexole,
aa dopamine D2/D3 receptor agonist, as an add-on
t
treatment in bipolar disorder (Goldberg et al., 2004; c
Zarate et al., 2004). Taken together, the above observa- w
tions suggest a coordinated upregulation of genes 1
leading to increased dopamine signaling. In the light
Bof the recent clinical data and human genetic linkage
Lstudies, it is tempting to speculate that PACAP might
ebe a therapeutic effector of lithium in bipolar disorder.
C
It is important to point out that we cannot yet say (
whether the therapeutic action of lithium is mediated s
by inhibition of IMPase, or GSK3β, or in fact any other C
tmolecular target. Indeed, it is possible that inhibition ofoth IMPase and GSK3β is required. The present study
id not, and by its design could not, assess the contri-
ution of GSK3β inhibition to gene regulation, which is
xpected to be considerable. Very recently, Klein and
oworkers have begun to dissect the molecular targets
ssociated with certain lithium-sensitive behaviors
sing wild-type and GSK3β mutant mice. Their data
oint to GSK3β as the relevant target of lithium in the
orced-swim test, which is a widely recognized pre-
ictor of antidepressant/anxiolytic-like drug efficacy
O’Brien et al., 2004).
onclusion
he most interesting finding in this study is that inositol
epletion effected by treatment with an agonist that
auses PI turnover and blockade of IMPase by lithium
ed to upregulation of the Adcyap1 (PACAP), Pam, and
ch genes. This trio of genes suggests that modulation
f dopamine signaling via regulation of TH activity
ould be a consequence of inositol depletion in the
rain. These findings suggest several lines of experi-
ents. Does chronic lithium treatment in rodents cause
hanges in brain PACAP levels, and is this brain region-
nd cell-specific? Is PACAP elevated in brains of
MPase knockout mice? Are PACAP levels in patients
ith bipolar disorder (measured in the cerebrospinal
luid) different than controls, and is this affected by
edication with lithium? Do changes in PACAP corre-
ate with symptomatic relief? In summary, the data pre-
ented here warrant further investigation of PACAP sig-
aling in the brain and of the orphan receptor GPR88
s potential new targets in bipolar disorder.
xperimental Procedures
ortical Slice Culture
ll animal procedures were approved by the Institutional Animal
are and Use Committee of Merck Research Laboratories. Male
prague-Dawley rats (w200 g, 7–8 weeks of age) were euthanized
y CO2 inhalation for 90 s and then decapitated. The brain was
apidly dissected out and placed in ice-cold Krebs-Ringer buffer
KRB: 1.2 mM KH2PO4, 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4,
.5 mM CaCl2, 25 mM NaHCO3, 11 mM D-glucose), which was con-
inuously bubbled with 95% O2/5% CO2 (carbogen). The right cere-
ral cortex was rapidly dissected and chopped into 350 m coronal
lices using a McIlwain tissue chopper (Stoetling Co.). All slices,
xcept the anterior and posterior two to three, were collected into
arbogen-bubbled ice-cold KRB and dispensed randomly to cul-
ure plates (two per well). This process reliably generated 24 slices
er animal, enough for 12 tests. Slices were maintained on porous
embrane inserts (Millipore PICM 030 50) at the gas-liquid inter-
ace in Neurobasal-A medium (Invitrogen) with 1X B27 supplement
Invitrogen) in polystyrene 6-well plates (Corning Costar). Neuroba-
al-A/B27 contains 38 M inositol. The culture plates were held in
tissue culture incubator at 34°C in a custom-made perspex box
hat was maintained under a slight positive pressure of humified
arbogen. One animal was processed per day. These methods
ere based upon those described previously (Banker and Goslin,
998; Wilhelmi et al., 2002).
iochemical Studies, RNA Preparation, and Slice Staining
iCl, carbachol, D-myo-inositol, and 5-[3H]-cytidine (solution in 2%
thanol, 15–25 Ci/mmol, 1 mCi/ml) were purchased from Sigma.
DP-DAG was estimated essentially as described by Atack et al.
1993). Briefly, the membrane inserts holding the radiolabeled
lices were transferred to an empty 6-well plate and 1 ml of 1:2
HCl3/MeOH as added to each well. Slices were transferred with
he solvent into 4 ml glass vials (Fisher Scientific) and incubated at
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869room temperature for 15 min. CHCl3 (0.8 ml) and water (0.8 ml)
were added followed by vigorous vortexing for 10 s. Phases were
separated by centrifugation, and the organic phase was transferred
to a 2 ml plastic tube and washed with 1 ml of 1:1 1 M HCl/MeOH.
Finally 0.2 ml of the organic phase was mixed with 5 ml scintillation
fluid (Ready-Safe, Beckman) and counted using a Liquid Scintilla-
tion Analyzer (Packard).
Total RNA was extracted and purified from slices using the Qia-
gen RNeasy purification kit. Slices were rinsed with 1 ml cold PBS
and transferred to a new tube with 0.6 ml kit lysis buffer. Slices
were homogenized using a hand-held homogenizer (PowerGen
125, Fisher) for 3 × 10 s on ice. RNA was purified following the
manufacturer’s instructions, but with an additional DNase I treat-
ment using the Ambion DNA-free kit following the manufacturer’s
instructions. RNA was finally eluted in 40–50 l diethylpyrocarbo-
nate-treated (DEPC) water. RNA concentration was measured by
UV spectrophotometry, and RNA quality was measured using Ag-
ilent’s 2100 Bioanalyzer and RNA 6000 Nano LabChip.
Brain slices were stained either immediately after sectioning or
after 1 day with various treatments. Slices were rinsed once with
KRB/HEPES (KRB as described above, but with 15 mM NaHCO3
and 10 mM HEPES) and incubated at room temperature (RT) either
for 5 min in 2.5 ml of 5 g/ml Hoechst 33342 (Molecular Probes) or
for 3 min in 2.5 ml of 4 M propidium iodide (Molecular Probes)
both in KRB/HEPES. Slices were rinsed once with KRB/HEPES at
RT (Hoechst staining) or three times (propidium iodide staining) and
transferred to 6-well plates with fresh KRB/HEPES for microscopy.
Slices were imaged using a Bio-Rad Radiance 2100 confocal laser-
scanning system coupled to a Nikon E600FN microscope using a
40× water-immersion objective. Propidium iodide was imaged
using one-photon excitation with a 543 nm Green HeNe laser, and
emitted light was collected using a 570 nm long-pass filter. Hoechst
dye was excited using two-photon excitation at 780 nm from a
Coherent Mira-verdi laser source, and emitted light was collected
using a 410–490 nm bandpass filter. Infrared light was blocked from
reaching the PMT using a 625 nm short-pass filter. Images were
acquired at 2 m intervals. A single maximal-intensity projection
image was processed using Image-Pro to count bright objects,
corresponding to nuclei. The number and diameter of positively
stained nuclei were quantified in 155 × 155 m regions.
Microarray Profiling
The protocol used for sample amplification and labeling utilizes two
rounds of a modified MMLV-RT-mediated reverse transcription pro-
tocol (Shannon, 2000). All samples were processed in parallel using
a Biomek FX liquid-handling robot. DNase-treated total RNA sam-
ples were quantified using RiboGreen (Molecular Probes) as de-
scribed by the manufacturer. One hundred ng of total RNA and 0.4
pmol of T7T18VN primer (5# AATTAATACGACTCACTATAGGGAG
ATTTTTTTTTTTTTTTTTTVN 3#, V = G, C, or T; N = A, G, C, or T)
were combined and brought to a final volume of 10.5 l with water.
The RNA was denatured, and the primer was annealed by heating
the sample to 65°C for 10 min followed by cooling to 4°C for 5 min.
The following components were added to the concentrations listed
up to a final reaction volume of 20 l: 50 mM Tris (pH 8.3), 75 mM
KCl, 3 mM MgCl2, 4 U/l RNAGuard, 0.5 mM each dNTP (dATP,
dCTP, dGTP, dTTP), 1.0 ng/l random hexamers, 10 mM dithiothrei-
tol, and 2.5 U/l MMLV-RT. The reaction was incubated for 2 hr at
40°C to generate double-stranded cDNA. The MMLV enzyme was
denatured by heating the reaction at 65°C for 15 min. For the first
in vitro transcription (IVT), the total volume of the reaction was in-
creased to 80 l with the following components to the final concen-
trations listed: 40 mM Tris (pH 7.5), 10.0 mM NaCl, 2.0 mM spermi-
dine, 14.25 mM MgCl2, 200 U/ml RNAGuard, 2.5 mM each NTP
(ATP, GTP, CTP, UTP), 7.5 mM dithiothreitol, 25 kU/ml T7 RNA poly-
merase, and 15 U/ml inorganic pyrophosphatase. The IVT reaction
was incubated for 4 hr at 40°C. The cRNA from the IVT reaction
was purified using the 96-well Qiagen RNeasy purification kit. The
cRNA was quantified using UV spectrophotometry and then evapo-
rated using an evaporative centrifuge at 50°C.
The cRNA was rehydrated with 10 l of 0.27 g/l random
9-mers followed by heating to 65°C for 10 min and cooling to 4°C
for 5 min. For cDNA synthesis, the reaction volume was increasedto 35 l with the following components to the listed concentrations:
50 mM Tris (pH 8.3), 75 mM KCl, 8 mM MgCl2, 0.5 mM each dNTP
(dATP, dCTP, dGTP, dTTP), 10 mM dithiothreitol, and 5.0 U/l Su-
perScript II. The generation of the cDNA:cRNA duplex is accom-
plished by incubating the reaction for 1 hr at 42°C. A size-exclusion
filter (Millipore Multiscreen) was used to remove unincorporated
random 9-mers. Four pmol of T7T18VN primer were added, and
the entire mixture was evaporated using an evaporative centrifuge
at 50°C.
The cDNA:cRNA and primer were rehydrated with 10.5 l of
water followed by heating the sample to 65°C for 10 min, followed
by cooling to 4°C for 5 min. The following components were added
to the concentrations listed in a final reaction volume of 20 l: 50
mM Tris (pH 8.3), 75 mM KCl, 3 mM MgCl2, 4 U/l RNAGuard, 0.5
mM each dNTP (dATP, dCTP, dGTP, dTTP), 1.0 ng/l random hex-
amers, 10 mM dithiothreitol, and 2.5 U/l MMLV-RT. This reaction
was incubated for 2 hr at 40°C to denature the cRNA and generate
double-stranded cDNA. The enzyme was denatured by heating the
reaction at 65°C for 15 min. For the IVT, the total volume of the
reaction was increased to 80 l with the following components at
the concentrations listed: 40 mM Tris (pH 7.5), 10.0 mM NaCl, 2.0
mM spermidine, 14.25 mM MgCl2, 200 U/ml RNAGuard, 2.5 mM
each (ATP, CTP, GTP), 1.88 mM UTP, 0.6 mM amino-allyl UTP, 7.5
mM dithiothreitol, 25 kU/ml T7 RNA polymerase, and 15 U/ml inor-
ganic pyrophosphatase. The label-incorporating IVT reaction was
incubated for 16 hr at 40°C. The cRNA from the in vitro transcription
reaction was purified using a 96-well Qiagen RNeasy purification
kit and quantified using UV spectrophotometer.
The final amino-allyl-cRNA was coupled to CyDye molecules,
fragmented, and hybridized to custom 60-mer oligonucleotide
microarrays (Agilent) as described (Hughes et al., 2001). Each sam-
ple was separately coupled to Cy3 and Cy5 and hybridized to the
oppositely coupled control sample. Thus, each pair of samples was
analyzed on two separate microarrays, termed a fluor-reversed pair
(FRP). The arrays were scanned using an Agilent DNA Microarray
Scanner, and array images were analyzed using custom Matlab
programs.
Microarray Data Analysis
The general quality of the hybridizations was excellent. However,
five samples were hybridized to new arrays when their initial hy-
bridizations did not meet our stringent standards. Since the expres-
sion data from the new hybridizations were highly correlated with
data from the initial hybridizations, to gain precision we calculated
weighted averages between the two, with weights based on the
reciprocal of the estimated measurement variance, and used the
weighted averages for all downstream analysis. Any reporter that
failed to give reliable data for five or more samples was deemed
unreliable and not analyzed.
An analysis of variance (ANOVA) model was fit separately to the
log ratios (Treatment versus LiCl + carbachol reference pool) for
each of the remaining 23,251 reporters. The ANOVA model con-
tained terms for both treatment (LiCl, LiCl + carbachol, or LiCl +
carbachol + inositol) and animal (1 or 2). Estimates of differences
(or fold changes) were obtained from the means calculated in the
ANOVA fit. Tests of significance were performed using a t statistic
constructed from these difference estimates and an empirical
bayesian estimate of error (Smyth, 2004). The strength of this ap-
proach is that for a particular gene, the error estimate is a combina-
tion of a gene-specific error estimate and a global error estimate
across all the genes.
RT-QPCR
Messenger RNA was amplified to produce antisense RNA (aRNA)
based on protocols developed by Eberwine and coworkers (Phillips
and Eberwine, 1996). All 36 samples were processed in parallel.
Total RNA (0.8 g) was used to prepare double-stranded (ds)-cDNA
using the SuperScript Double-Stranded cDNA Synthesis kit (Invitro-
gen) with oligo-dT primers containing a T7 polymerase promoter
sequence (5#-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGG
CGGT24-3#) following the manufacturer’s instructions except that
the final concentration of primer was 1 M and we added 0.25 l
of 40 units/l RNASEOUT Ribonuclease Inhibitor (Invitrogen 10777-
Neuron
870019) in the first strand synthesis step without changing the reaction e
ovolume. Product ds-cDNA was purified using the MiniElute Reac-
tion Cleanup kit (Qiagen) following the manufacturer’s instructions. o
2The AmpliScribe T7 Transcription (Epicentre) kit was used to pre-
pare aRNA by in vitro transcription from the total ds-cDNA from s
meach sample according to the manufacturer’s instructions with the
following exceptions: we scaled up the reaction mixture 2-fold, we c
oused 4 l of 1000 units/l T7 RNA polymerase (Epicentre TH950k)
per reaction, and we included 0.5 l of 40 units/l RNASEOUT Ri-
bonuclease Inhibitor in each reaction. The reaction was incubated
at 37°C for 4 hr. RNA was purified using the RNeasy Mini kit (Qia- S
gen). RNA concentration was measured by UV spectrophotometry, T
and RNA quality was measured using Agilent’s 2100 Bioanalyzer c
and RNA 6000 Nano LabChip. c
One g of aRNA per sample was used to prepare the cDNA PCR
template using 1 g random hexamer primer (Invitrogen 48190-
011), using the first-strand synthesis portion of the SuperScript A
Double-Stranded cDNA Synthesis kit (Invitrogen) following the
manufacturer’s instructions. W
PCR reactions were carried out in 384-well plates using the As- n
says-on-Demand Gene Expression Products protocols available s
from Applied Biosystems using the cDNA derived from 2 ng aRNA i
per reaction. Custom-designed primers and probes were used at l
200 nM. Reaction components were added to assay plates using a O
Beckman-Coulter MultiMek pipeting robot. The commercial assays s
and custom-prepared primer/probe sets used in this study are
summarized in Table S2. R
Each aRNA sample was tested for contamination with DNA by R
running a small sample through the cDNA synthesis reaction with- A
out reverse transcriptase, and running RT-QPCR assays for b-2 P
microglobulin (B2m), glucuronidase b (Gusb), and Jun. None of the
samples were contaminated. R
We used multiple endogenous reference genes in the RT-QPCR
experiment to build redundancy into this aspect of the analysis. A
This required the analysis to be carried out in a one plate–one l
RNA–many genes configuration, which in turn necessitates com-
Aparison of Ct values across plates. We validated this experimen-
mtally (data not shown). Two rat genes recommended as endoge-
inous references by Applied Biosystems Inc. are B2m and Gusb.
ANeither of these genes were regulated by the treatments based on
sthe microarray data set (data not shown). Two other genes, vesicle-
passociated membrane protein 1 (Vamp1) and X-ray repair cross-
complementing group 1 protein (Xrcc1), were identified in the A
microarray data set as being very confidently not differentially ex- t
pressed across treatments (data not shown). a
Samples (one per plate) were analyzed sequentially as blocks of B
samples grouped by animal. Each block took 3 days (maximum B
three plates per day) to process, and a fresh batch of reagents was M
prepared for each block. Within each block, the sample order was
B
randomized using a Latin square design, with a different design for
d
each block. In this way, between animal, between day of sacrifice,
4
and between reagent batch variabilities were segregated together,
Bwhereas interplate variability was randomized across samples and
atreatments. Four technical replicates were performed for each
passay.
4In addition to test wells, every plate included an assay of B2m
Bin a cDNA sample derived from RNA from rat cortical slice tissue
Pprocessed in the same way as the test samples. These wells were
eused to set a consistent plate-to-plate threshold fluorescence level
dfor the determination of Ct, even though Ct is theoretically indepen-
odent of the threshold setting.
5
BRT-QPCR Data Analysis
S
Three of the 33 samples analyzed by RT-QPCR were not used due
V
to quality control indications. The data for different genes were not
m
pooled; each gene was analyzed independently of all others. The
h
two sets of data for the Crem gene were also analyzed separately.
6
Ct values were calculated using a means-normalized aggregate
Bof three endogenous reference genes (B2m, Gusb, and Xrcc1). For
aeach set of gene data, a mixed linear model (Searle et al., 1992)
mwas fit with Ct as the dependent variable, the three treatments
4as fixed effects, and both animal and plate as separate random
effects. Two-sided p values were obtained for the treatment differ- Cnces LC versus L and LCI versus LC, based on the error structure
f the mixed model. R software (version 1.9.1, http://www.r-project.
rg/) and the nlme package (version 7.1-48; Pinhiero and Bates,
000) were used to perform the analyses. The results of the analy-
is are reported in Table S3, including the derived value for the
ean Ct and the standard error of that mean value. The fold
hange is equal to 2 raised to the power of the numerical value
f Ct.
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